ARPA-H — $63M Initiative and Seven Organizations Selected for AI Cardiovascular Care Platform
ENTITYARPA-H has tapped seven organizations to participate in its $63 million effort to build FDA-authorized AI agents for heart failure care. The initiative — previously reported as the ADVOCATE program — aims to develop autonomous or semi-autonomous AI systems capable of managing aspects of heart failure treatment, with FDA authorization as a required endpoint rather than an aspirational goal. The selection of seven organizations for the cardiovascular AI platform reflects ARPA-H's strategy of funding parallel development tracks, allowing different technical approaches to compete while sharing the common regulatory target of FDA authorization. Heart failure was selected as a priority indication due to its high prevalence, significant readmission burden, and the complexity of medication titration that makes it a candidate for AI-assisted management. The $63 million investment raises governance questions that have been flagged by legal and clinical commentators: autonomous AI agents making or recommending heart failure treatment decisions carry liability implications that existing frameworks do not clearly address. ARPA-H's requirement for FDA authorization as a program deliverable — rather than leaving regulatory strategy to individual awardees — represents an attempt to build accountability into the initiative's structure from the outset.
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.